BioCentury | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BioCentury | Oct 4, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2017

...Inc. (NASDAQ:MRTX) Clinical News Neurology Neurology O-sialoglycoprotein endopeptidase (OSGEP) Mutations in OSGEP, TP53RK, TPRKB or LAGE3...
...Institute ; Harvard Medical School Distillery Techniques TP53 regulating kinase (TP53RK) TP53RK binding protein (TPRKB) L antigen family member 3 (LAGE3)...
BioCentury | Sep 27, 2017
Distillery Techniques

Biomarkers

...complex: O-sialoglycoprotein endopeptidase (OSGEP) , TP53 regulating kinase (TP53RK) , TP53RK binding protein (TPRKB) and L antigen family member 3 (LAGE3)...
...with normal expression of OSGEP and TPRKB. In mouse embryos, knockout of OSGEP, TPRKB or LAGE3...
...email: corinne.antignac@inserm.fr CONTACT: Friedhelm Hildebrandt, Harvard Medical School, Boston, Mass. email: Friedhelm.Hildebrandt@childrens.harvard.edu Winnie Pong Harvard Medical School Imagine Institute L antigen family member 3 (LAGE3) O-sialoglycoprotein...
BioCentury | Jun 15, 2017
Clinical News

Adaptimmune starts Phase I of T cell therapy plus Keytruda

Adaptimmune Therapeutics plc (NASDAQ:ADAP) began a Phase I trial of NY-ESO SPEAR T-cell therapy (ADAP NY-ESO TCR, GSK3377794) plus Keytruda pembrolizumab to treat multiple myeloma (MM). The open-label, U.S. trial will evaluate safety in up...
BioCentury | Oct 24, 2013
Strategy

Driving CAR-based cellular therapies

Adoptive T cell therapies were first developed in the mid-1980s but only recently entered the limelight owing to dramatic clinical results achieved with the latest incarnation, chimeric antigen receptor-based cell therapies. Novartis AG 's 2012...
BioCentury | Jul 29, 2013
Clinical News

Enhanced TCR Therapy: Phase I/II started

Adaptimmune began an open-label, U.S. Phase I/IIa trial to evaluate enhanced TCR therapy in about 6 patients with the human leukocyte antigen serotype A201 (HLA-A201) allele and whose tumors express NY-ESO-1 and LAGE1. The company...
BioCentury | Dec 17, 2012
Clinical News

Enhanced TCR Therapy for MM: Preliminary Phase I/II data

Preliminary data from 13 evaluable MM patients in a single-arm, open-label, U.S. Phase I/II trial showed that enhanced TCR therapy given in conjunction with autologous stem cell transplantation led to an ORR of 77% at...
BioCentury | Aug 9, 2004
Product Development

The other way around EGF

In the late 1980s, when Cuban scientists began developing active and passive immunotherapies against epidermal growth factor (EGF) and its receptor, virtually all other efforts were targeting EGFr rather than the growth factor itself. Of...
Items per page:
1 - 8 of 8